Notice of Closed Meeting, 8915 [2021-02738]
Download as PDF
Federal Register / Vol. 86, No. 26 / Wednesday, February 10, 2021 / Notices
certain information to assure the dutyfree entry of the supplies.
e. Construction provisions and
clauses:
• 52.225–9, Buy American—
Construction Materials
• 52.225–10, Notice of Buy American
Requirement—Construction Materials
• 52.225–11, Buy AmericanConstruction Materials Under Trade
Agreements
• 52.225–12, Notice of Buy American
Requirement—Construction Materials
under Trade Agreements
• 52.225–21, Required Use of American
Iron, Steel and Manufactured Goods—
Buy American—Construction
Materials
• 52.225–23, Required Use of American
Iron, Steel and Manufactured Goods—
Buy American—Construction
Materials Under Trade Agreements
The listed provisions and clauses
provide that an offeror or contractor
requesting to use foreign construction
material due to unreasonable cost of
domestic construction material shall
provide adequate information to permit
evaluation of the request.
C. Annual Burden
Respondents: 8,771.
Total Annual Responses: 43,891.
Total Burden Hours: 40,738.
D. Public Comment
A 60-day notice was published in the
Federal Register at 85 FR 63276, on
October 7, 2020. No comments were
received.
Obtaining Copies: Requesters may
obtain a copy of the information
collection documents from the GSA
Regulatory Secretariat Division, by
calling 202–501–4755 or emailing
GSARegSec@gsa.gov. Please cite OMB
Control No. 9000–0024, Buy American,
Trade Agreements, and Duty-Free Entry.
Janet Fry,
Director, Federal Acquisition Policy Division,
Office of Governmentwide Acquisition Policy,
Office of Acquisition Policy, Office of
Governmentwide Policy.
[FR Doc. 2021–02689 Filed 2–9–21; 8:45 am]
BILLING CODE 6820–EP–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
VerDate Sep<11>2014
18:53 Feb 09, 2021
Jkt 253001
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
Panel 1, Panel 2, and Panel 3: GH21–
003, Advancing Public Health Research
in Kenya; GH21–004, Conducting
Research to Inform Pandemic Response
and Recovery of Emergency-Affected
Populations by Determining Public
Health Needs, Improving Methods, and
Integrating Services to Mitigate
Morbidity and Mortality; and GH21–
006, Strengthening Public Health
Research and Implementation Science
(Operations Research) to Control and
Eliminate Infectious Diseases Globally.
Dates: March 30–31, 2021 and April
1, 2021.
Time: 9:00 a.m.–2:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Hylan Shoob, Ph.D., Scientific Review
Officer, Center for Global Health, CDC,
1600 Clifton Drive, Atlanta, Georgia
30329–4027, Telephone (404) 639–4796,
HShoob@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–02738 Filed 2–9–21; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
8915
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP)–DP21–002,
Epidemiologic Cohort Study of
Interstitial Cystitis; Amended Notice of
Meeting
Notice is hereby given of a change in
the meeting of the Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP)–DP21–
002, Epidemiologic Cohort Study of
Interstitial Cystitis, March 30, 2021,
10:00 a.m.–6:00 p.m., EST, which was
published in the Federal Register on
Friday, December 11, 2020, Volume 85,
Number 239, page 80107.
The meeting on March 30, 2021 is
being amended to change the time and
should read as follows:
Time: 12:00 p.m.–3:00 p.m., EDT.
The meeting is closed to the public.
For Further Information Contact: Jaya
Raman, Ph.D., Scientific Review Officer,
National Center for Chronic Disease
Prevention and Health Promotion, CDC,
4770 Buford Highway, Mailstop S107–8,
Atlanta, Georgia 30341, Telephone (770)
488–6511, JRaman@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–02736 Filed 2–9–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
E:\FR\FM\10FEN1.SGM
10FEN1
Agencies
[Federal Register Volume 86, Number 26 (Wednesday, February 10, 2021)]
[Notices]
[Page 8915]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02738]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--Panel 1, Panel 2, and Panel 3:
GH21-003, Advancing Public Health Research in Kenya; GH21-004,
Conducting Research to Inform Pandemic Response and Recovery of
Emergency-Affected Populations by Determining Public Health Needs,
Improving Methods, and Integrating Services to Mitigate Morbidity and
Mortality; and GH21-006, Strengthening Public Health Research and
Implementation Science (Operations Research) to Control and Eliminate
Infectious Diseases Globally.
Dates: March 30-31, 2021 and April 1, 2021.
Time: 9:00 a.m.-2:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Hylan Shoob, Ph.D., Scientific
Review Officer, Center for Global Health, CDC, 1600 Clifton Drive,
Atlanta, Georgia 30329-4027, Telephone (404) 639-4796, [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-02738 Filed 2-9-21; 8:45 am]
BILLING CODE 4163-18-P